Objective:

The article examines the objective, findings, and clinical context described in Gene Therapy for IRDs: Real-World Lessons and New Directions.

Approach:

• Luxturna: Nagiel reviewed post-authorization safety experience with voretigene neparvovec-rzyl after treatment of hundreds of patients worldwide.
• OPGx-BEST1: He presented early findings from a five-patient study of gene therapy for autosomal recessive and dominant BEST1-related retinal diseases.

Key Findings:

• Real-world safety data for Luxturna were described as consistent with clinical-trial experience.
• Chorioretinal atrophy was reported after authorization and was not identified in the trials; Nagiel said it raises the possibility that certain vectors in particular settings could contribute to photoreceptor and retinal pigment epithelium degeneration.
• Nagiel said the atrophy had not so far limited the benefits patients experience.
• In five patients treated with OPGx-BEST1, the therapy was described as well tolerated, with no major safety issues and signs of potential efficacy.

Interpretation:

Nagiel said the OPGx-BEST1 findings require further evaluation in cohort two, which is planned to include a higher dose and more patients.

Limitations:

• The OPGx-BEST1 findings were preliminary and involved five patients.
• The context provides no detailed efficacy measures, follow-up duration, or quantitative safety results.

Conclusion:

The presentation covered long-term real-world observations with Luxturna and early safety and potential efficacy signals from OPGx-BEST1.

Sources:

• Provided article context: 2026 SARyV Meeting transcript